from SCIENCE to PHARMA (FSTP) - Board Certified MSL training’s Post

📊 Top Pharmas by 2024 Pipeline Size 👇 🏆 Roche leads the ranking with 218 products in the R&D pipeline closely followed by Pfizer. 🔎 Among the top 15 companies based on products in the pipeline, 6 were from the United States. 📈 R&D trends include a resurgence in investment and pipeline activity with a focus on obesity drugs, radiopharmaceuticals, and targeted therapies in oncology. As I am seeing a lot of discussions around large pharma R&D productivity - let's also consider R&D investments per company 👇 Merck - $30.5 billion Roche- $15.56 billion Johnson & Johnson– $15.09 billion Novartis– $ 11.37 billion AstraZeneca– $10.94 billion Pfizer– $10.58 billion Eli Lilly and Company- $9.31 billion Bristol Myers Squibb– $9.21 billion AbbVie– $7.68 billion Sanofi– $7.18 billion Investments represented here are strategic acquisitions to expand a company’s prowess in a particular area - or investments for in-licensing drug candidates to beef up their pipelines. Data: As of January 2024 🙏 Sources: Citeline, Pharmaceutical Technology & Company Annual reports 👩⚕️ 💊 Have you joined the MSL and medical affairs linkedin community yet? Over 21.000 med. affairs professionals across the globe sharing jobs, tips and actively networking. 🛎 👉 This is the link: https://lnkd.in/gZ_mBprH Nice post by Nicolas Schmitz

📊 Top Pharmas by 2024 Pipeline Size 👇 🏆 Roche leads the ranking with 218 products in the R&D pipeline closely followed by Pfizer. 🔎 Among the top 15 companies based on products in the pipeline, 6 were from the United States. 📈 R&D trends include a resurgence in investment and pipeline activity with a focus on obesity drugs, radiopharmaceuticals, and targeted therapies in oncology. As I am seeing a lot of discussions around large pharma R&D productivity - let's also consider R&D investments per company 👇 Merck - $30.5 billion Roche- $15.56 billion Johnson & Johnson– $15.09 billion Novartis– $ 11.37 billion AstraZeneca– $10.94 billion Pfizer– $10.58 billion Eli Lilly and Company- $9.31 billion Bristol Myers Squibb– $9.21 billion AbbVie– $7.68 billion Sanofi– $7.18 billion Investments represented here are strategic acquisitions to expand a company’s prowess in a particular area - or investments for in-licensing drug candidates to beef up their pipelines. Data: As of January 2024 🙏 Sources: Citeline, Pharmaceutical Technology & Company Annual reports If you like this content, ♻️ Repost it to your network and follow Akhil Choudhary✨️🧠 for more such insights.

Would be interesting to analyze what percentage of these pipelines is worthy of attaining blockbuster status.

I always enjoy learning about pipelines and eagerly awaiting the next post by Nicolas which will breakdown phases of the studies in each pipeline.

📊 Top Pharmas by 2024 Pipeline Size 👇 🏆 Roche leads the ranking with 218 products in the R&D pipeline closely followed by Pfizer. 🔎 Among the top 15 companies based on products in the pipeline, 6 were from the United States. 📈 R&D trends include a resurgence in investment and pipeline activity with a focus on obesity drugs, radiopharmaceuticals, and targeted therapies in oncology. As I am seeing a lot of discussions around large pharma R&D productivity - let's also consider R&D investments per company 👇 Merck - $30.5 billion Roche- $15.56 billion Johnson & Johnson– $15.09 billion Novartis– $ 11.37 billion AstraZeneca– $10.94 billion Pfizer– $10.58 billion Eli Lilly and Company- $9.31 billion Bristol Myers Squibb– $9.21 billion AbbVie– $7.68 billion Sanofi– $7.18 billion Investments represented here are strategic acquisitions to expand a company’s prowess in a particular area - or investments for in-licensing drug candidates to beef up their pipelines. Data: As of January 2024 🙏 Sources: Citeline, Pharmaceutical Technology & Company Annual reports

In the land of market capitalization, which pharmaceutical companies reign supreme? 👑 According to companiesmarketcap.com, Eli Lilly and Company and Novo Nordisk have significantly higher market capitalizations compared to their competitors in the pharmaceutical industry due to several factors. 𝐒𝐩𝐞𝐜𝐢𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐇𝐢𝐠𝐡-𝐆𝐫𝐨𝐰𝐭𝐡 𝐀𝐫𝐞𝐚𝐬: Eli Lilly has a strong portfolio in areas like diabetes, oncology, immunology, and neuroscience. Particularly, their diabetes treatments, including Trulicity and Mounjaro, have been very successful, leading to strong revenue growth. Additionally, their pipeline of drugs in oncology and Alzheimer's disease (like Donanemab) is promising, attracting substantial investor interest. Novo Nordisk is a leader in diabetes care and has seen tremendous success with its GLP-1 receptor agonists, such as Ozempic and Wegovy, which are also popular for weight loss. The rising global prevalence of diabetes and obesity, combined with Novo Nordisk's strong position in these markets, has driven its market cap significantly higher. 𝐒𝐭𝐫𝐨𝐧𝐠 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐏𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞: Both companies have shown strong revenue growth and profitability. Consistent financial performance, high margins, and successful drug launches have led to a higher valuation by the market. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐧𝐭𝐢𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐂𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐜𝐞: Investors are confident in the future prospects of both companies due to their innovative drug pipelines and leadership in growing therapeutic areas. This confidence is reflected in their high market capitalizations. 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐚𝐜𝐡 𝐚𝐧𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐡𝐚𝐫𝐞: Both companies have a strong global presence, with substantial market share in their respective fields. Their ability to penetrate and dominate key markets, particularly in high-growth regions like North America and Europe, adds to their market value. 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐚𝐧𝐝 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Eli Lilly and Novo Nordisk have robust drug development pipelines with several potential blockbuster drugs. This has resulted in strong market expectations for future growth, contributing to their high market capitalizations. What is for certain is that these rankings change significantly over the years - who do you think will be the next leader in market capitalization in the pharmaceutical industry? Comment below! #pharma #pharmaceutical #marketcap

🔎 Among the top 15 companies based on products in the pipeline, 6 were from the United States. 📈 R&D trends include a resurgence in investment and pipeline activity with a focus on obesity drugs, radiopharmaceuticals, and targeted therapies in oncology. As I am seeing a lot of discussions around large pharma R&D productivity - let's also consider R&D investments per company 👇 Merck - $30.5 billion Roche- $15.56 billion Johnson & Johnson– $15.09 billion Novartis– $ 11.37 billion AstraZeneca– $10.94 billion Pfizer– $10.58 billion Eli Lilly and Company- $9.31 billion Bristol Myers Squibb– $9.21 billion AbbVie– $7.68 billion Sanofi– $7.18 billion Investments represented here are strategic acquisitions to expand a company’s prowess in a particular area - or investments for in-licensing drug candidates to beef up their pipelines. Data: As of January 2024 🙏 Sources: Citeline, Pharmaceutical Technology & Company Annual reports

🌟 Exploring the Immuno-Oncology Landscape 🌟 The immuno-oncology drugs market has experienced remarkable growth, with projections pointing towards continued expansion. Understanding the key drivers and trends is crucial for stakeholders navigating this dynamic sector. Market Growth and Projections From $92.78 billion in 2023, the market surged to $105.64 billion in 2024, boasting a notable Compound Annual Growth Rate (CAGR) of 13.9%. Future forecasts predict sustained growth, reaching $175.05 billion by 2028, with a CAGR of 13.5%. Contributing Factors Numerous elements propel this growth, including the global rise in cancer incidences, robust economic growth in emerging markets, increased healthcare spending, and substantial investments in pharmaceutical Research and Development (R&D). Factors Influencing Market Dynamics Growth Drivers Growing emphasis on immunotherapy drugs for cancer treatment. Continuous product innovations. Expanded investments in immuno-oncology. Market Restraints High costs associated with immuno-oncology therapies. Limited healthcare accessibility. Pricing constraints imposed by regulatory bodies. Significant R&D expenses. Patent expiration of current drugs. For deeper insights, consult The Business Research Company's Immuno-Oncology Drug Global Market Report 2024. Let's embrace the opportunities and challenges shaping the future of immuno-oncology together! 🚀 Read More @ https://lnkd.in/gwFXXwCw #ImmunoOncology #MarketTrends #HealthcareInnovation

The biologic therapeutics drugs market is experiencing phenomenal growth, revolutionizing healthcare. These innovative drugs, derived from living cells, are making a significant impact on treating chronic diseases like cancer and autoimmune disorders. I recall a conversation with a specialist who emphasized how biologics have provided hope where traditional treatments fell short. The expanding market size underscores the increasing reliance on personalized medicine, offering targeted and effective solutions. It's exciting to witness this shift towards more precise and patient-centric care. The global biologic therapeutics drugs market was valued at USD 469.7 billion in 2023, growing at a CAGR of 12.2% from 2024 to 2033. The market is expected to reach USD 1485.0 billion by 2033. https://lnkd.in/dZbu2FDf What are your thoughts on the rise of biologic therapies in healthcare? Amgen., AbbVie, Eli Lilly and Company, GSK, Sanofi, AstraZeneca #Biologics #HealthcareInnovation #PersonalizedMedicine #Pharmaceuticals #ChronicDisease

📊 Top Pharmas by 2024 Pipeline Size 👇 🏆 Roche leads the ranking with 218 products in the R&D pipeline closely followed by Pfizer. 🔎 Among the top 15 companies based on products in the pipeline, 6 were from the United States. 📈 R&D trends include a resurgence in investment and pipeline activity with a focus on obesity drugs, radiopharmaceuticals, and targeted therapies in oncology. As I am seeing a lot of discussions around large pharma R&D productivity - let's also consider R&D investments per company 👇 Merck - $30.5 billion Roche- $15.56 billion Johnson & Johnson– $15.09 billion Novartis– $ 11.37 billion AstraZeneca– $10.94 billion Pfizer– $10.58 billion Eli Lilly and Company- $9.31 billion Bristol Myers Squibb– $9.21 billion AbbVie– $7.68 billion Sanofi– $7.18 billion Investments represented here are strategic acquisitions to expand a company’s prowess in a particular area - or investments for in-licensing drug candidates to beef up their pipelines. Data: As of January 2024